Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 79

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 79
---
 | ​ |
|:-----------------------------------------------------------------------------------------------------------------------------------------------------------|:--|:--|-------:|:--|:--|------:|:--|
| Pro forma decrease in net tangible book value per share attributable to the Vivus Adjustments                                                              | ​ | $ |  -0.22 | ​ | ​ |     ​ | ​ |
| Pro forma net tangible book value per share as of September 30, 2024, after giving effect to Vivus Adjustments                                             | ​ | $ |  -0.90 | ​ | ​ |     ​ | ​ |
| Pro forma as adjusted increase (or decrease) in net tangible book value per share attributable to investors in this offering and the Pro Forma Adjustments | ​ | $ |   0.89 | ​ | ​ |       | ​ |
| Pro Forma as adjusted net tangible book value per share after giving effect to this offering                                                               | ​ | ​ |        | ​ | $ | -0.01 | ​ |
| Dilution per share to investors participating in this offering                                                                                             | ​ | ​ |        | ​ | $ |  0.25 | ​ |

The foregoing table does not give effect to (i) the adjustment to the conversion price of the Company’s Series A Preferred Stock and related warrants as a result of this offering due to the anti-dilution provisions contained in such Series A Preferred Stock and warrants, and (ii) the issuance of the Stock Awards in the amount of 2,200,000 shares of restricted shares of common stock to be issued to certain directors and officers of the Company, subject to the closing of this offering. Further, the foregoing table does not take into account further dilution to investors in this offering that could occur upon the exercise of outstanding options and warrants, including the Series Warrants offered in this offering, having a per share exercise price less than the public offering price per share in this offering. The foregoing discussion and table also does not take into account any “alternative cashless exercises” of the Series B Warrants, pursuant to which a holder of a Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of common stock that would be issuable upon a cash rather than a cashless exercise of the Series B Warrant and (ii) 3.0 The table above is based on 10,014,872 shares of our common stock outstanding as of September 30, 2024, and excludes